Clinical trial · Observational
The EXPLORE MG Registry for Myasthenia Gravis
Exploring Outcomes and Characteristics of Myasthenia Gravis: The EXPLORE MG Registry
NCT03792659CI-TRIAL-00098055recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to create a Yale University Department of Neurology Myasthenia Gravis (MG) registry that will be used for current and future research projects involving the study of Myasthenia Gravis.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Myasthenia Gravis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood Sample Draw | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Neurological Outpatients
- description
- Participants in this group will be recruited from the outpatient clinical population at the Yale University Department of Neurology. Treating physicians will make the initial determination of patients' potential eligibility to participate in the study.
- interventionNames
- Other: Blood Sample Draw
Primary outcomes (1)
- measure
- The number of successful blood draws will be reported at the conclusion of the sample collection
- timeFrame
- 8 years
- description
- Successful Collection of Blood
Secondary outcomes (1)
- measure
- The number of stool samples collected will be reported at the conclusion of the sample
- timeFrame
- 8 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients diagnosed with Myasthenia Gravis presenting to the Yale Department of Neurology for clinical care or research interventions will be invited to donate their biological specimens/clinical data. Exclusion Criteria: * Failure to meet the Inclusion Criteria.
References
Publications (2)
- BACKGROUNDAnil R, Kumar A, Alaparthi S, Sharma A, Nye JL, Roy B, O'Connor KC, Nowak RJ. Exploring outcomes and characteristics of myasthenia gravis: Rationale, aims and design of registry - The EXPLORE-MG registry. J Neurol Sci. 2020 Jul 15;414:116830. doi: 10.1016/j.jns.2020.116830. Epub 2020 Apr 16. PMID 32388060
- DERIVEDMcLaren N, Gutierrez AZ, Joo D, Roy B, Park M, Nowak RJ. Variations in clinical features and disease burden of myasthenia gravis between racial and ethnic groups: A retrospective cohort study of two national databases. J Neurol Sci. 2026 Feb 15;481:125740. doi: 10.1016/j.jns.2026.125740. Epub 2026 Jan 5. PMID 41500177